Ishwarlal Jialal
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ishwarlal Jialal has a total of 82 co-authors. Here are the top co-authors by number of shared publications:
Sridevi Devaraj
Texas Children's Hospital, Baylor College of Medicine, Houston, Texas, USA ; 2 Children's Hospital of Oakland Research Institute, Oakland, CA, USA ; 3 UC Davis Medical Center, Sacramento, CA, USA
13 shared publications- Sridevi Devaraj
C Department of Pathology and Immunology, Baylor College of Medicine and Texas Children's Hospital, Houston, TX, USA
7 shared publications Roma Pahwa
Department of Pathology and Laboratory Medicine, UC Davis Medical Center , Sacramento, California
5 shared publicationsS Devaraj
Department of Pathology & Immunology, Baylor College of Medicine and Texas Children's Hospital, Houston, TX, USA
5 shared publicationsS. Devaraj
5 shared publicationsBeverley Adams-Huet
Division of Biostatistics, University of Texas Southwestern Medical Center , Dallas, Texas
4 shared publications
Latest Publications
- Open Access
- 14 November 2016
- Published by Wiley in Journal of Diabetes Research
- Vol. 2016, 1-2
Erratum to “Hyperglycemia Induces Toll-Like Receptor-2 and -4 Expression and Activity in Human Microvascular Retinal Endothelial Cells: Implications for Diabetic Retinopathy”
[This corrects the article DOI: 10.1155/2014/790902.].
- 14 November 2016
- Published by Wiley in Journal of Diabetes Research
- Vol. 2016, 1-2
Open AccessErratum to “Hyperglycemia Induces Toll-Like Receptor-2 and -4 Expression and Activity in Human Microvascular Retinal Endothelial Cells: Implications for Diabetic Retinopathy”
[This corrects the article DOI: 10.1155/2014/790902.].
- Open Access
- 12 July 2016
- Published by Oxford University Press (OUP) in Laboratory Medicine
- Vol. 47 (3) , 259-262
Folate Insufficiency Due to Celiac Disease in a 49-Year-Old Woman of Southeast Asian-Indian Ethnicity: Table 1.
The clinical presentation of celiac disease has evolved from chronic diarrhea and malnutrition to mild nutrient insufficiencies. Recently diagnosed adults with celiac disease should be assessed for micronutrient deficiencies because early institution of a gluten-free diet (GFD) prevents morbidity and reduces the incidence of gastrointestinal malignant neoplasms and osteoporosis. In this report, we present the case of a 49-year-old woman of Southeast Asian–Indian descent living in the United States who had folate insufficiency, as manifested by low serum and red blood cell (RBC) folate levels. Further investigation, including serologic testing and intestinal biopsy, confirmed a diagnosis of celiac disease and other nutrient deficiencies. Managing the condition of this patient with folate supplements and implementation of a recommended GFD reversed the folate insufficiency. In conclusion, when serum and/or RBC levels are low in a person of Southeast Asian-Indian descent living in a country with folate fortification of the grain supply, such as the United States, the medical team needs to look for an organic cause, as in our patient, to diagnose and manage celiac disease early and, hopefully, forestall complications.
- 12 July 2016
- Published by Oxford University Press (OUP) in Laboratory Medicine
- Vol. 47 (3) , 259-262
Open AccessFolate Insufficiency Due to Celiac Disease in a 49-Year-Old Woman of Southeast Asian-Indian Ethnicity: Table 1.
The clinical presentation of celiac disease has evolved from chronic diarrhea and malnutrition to mild nutrient insufficiencies. Recently diagnosed adults with celiac disease should be assessed for micronutrient deficiencies because early institution of a gluten-free diet (GFD) prevents morbidity and reduces the incidence of gastrointestinal malignant neoplasms and osteoporosis. In this report, we present the case of a 49-year-old woman of Southeast Asian–Indian descent living in the United States who had folate insufficiency, as manifested by low serum and red blood cell (RBC) folate levels. Further investigation, including serologic testing and intestinal biopsy, confirmed a diagnosis of celiac disease and other nutrient deficiencies. Managing the condition of this patient with folate supplements and implementation of a recommended GFD reversed the folate insufficiency. In conclusion, when serum and/or RBC levels are low in a person of Southeast Asian-Indian descent living in a country with folate fortification of the grain supply, such as the United States, the medical team needs to look for an organic cause, as in our patient, to diagnose and manage celiac disease early and, hopefully, forestall complications.
- 8 June 2016
- Published by Elsevier in Atherosclerosis
- Vol. 251, 504-506
Hypoglycemia and the predisposition to cardiovascular disease: Is the pro-inflammatory-pro-coagulant diathesis a plausible explanation?
- 8 June 2016
- Published by Elsevier in Atherosclerosis
- Vol. 251, 504-506
Hypoglycemia and the predisposition to cardiovascular disease: Is the pro-inflammatory-pro-coagulant diathesis a plausible explanation?
- 1 June 2016
- Published by SAGE Publications in Metabolic Syndrome and Related Disorders
- Vol. 14 (5) , 239-241
Hyperglycemia Induces Toll-Like Receptor Activity Through Increased Oxidative Stress
Hyperglycemia-induced oxidative stress and inflammation are central in the genesis of diabetic vascular complications. Toll-like receptors (TLRs) play a crucial role in promoting inflammatory responses and are known to be activated in diabetic patients. Also in animal models, they have been shown to have a role in the pathogenesis of diabetic vasculopathies. However, the mechanisms underlying this increase in TLR activity in diabetes are not well documented. Since increased reactive oxygen species (ROS) are also produced in various tissues under diabetic conditions, we postulated that ROS act as a potential activator of TLR. Several studies support our hypothesis that hyperglycemia-induced oxidative stress appears to be an important factor in promoting TLR activity in monocytes, both microvascular and macrovascular endothelial cells and cardiomyocytes and in animal models. Most importantly, the increase in ROS and TLR activity is ameliorated with antioxidant strategies. Thus, targeting ROS/NADPH oxidase with small molecular inhibitors could be a promising strategy to reduce both oxidative stress and TLR-mediated inflammation in diabetic vascular diseases.
- 1 June 2016
- Published by SAGE Publications in Metabolic Syndrome and Related Disorders
- Vol. 14 (5) , 239-241
Hyperglycemia Induces Toll-Like Receptor Activity Through Increased Oxidative Stress
Hyperglycemia-induced oxidative stress and inflammation are central in the genesis of diabetic vascular complications. Toll-like receptors (TLRs) play a crucial role in promoting inflammatory responses and are known to be activated in diabetic patients. Also in animal models, they have been shown to have a role in the pathogenesis of diabetic vasculopathies. However, the mechanisms underlying this increase in TLR activity in diabetes are not well documented. Since increased reactive oxygen species (ROS) are also produced in various tissues under diabetic conditions, we postulated that ROS act as a potential activator of TLR. Several studies support our hypothesis that hyperglycemia-induced oxidative stress appears to be an important factor in promoting TLR activity in monocytes, both microvascular and macrovascular endothelial cells and cardiomyocytes and in animal models. Most importantly, the increase in ROS and TLR activity is ameliorated with antioxidant strategies. Thus, targeting ROS/NADPH oxidase with small molecular inhibitors could be a promising strategy to reduce both oxidative stress and TLR-mediated inflammation in diabetic vascular diseases.
- 1 June 2016
- Published by Elsevier in Atherosclerosis
- Vol. 249, 230-232
Cadmium and atherosclerosis: Heavy metal or singing the blues?
- 1 June 2016
- Published by Elsevier in Atherosclerosis
- Vol. 249, 230-232
Cadmium and atherosclerosis: Heavy metal or singing the blues?
- 1 April 2016
- Published by AME Publishing Company in Translational Pediatrics
- Vol. 5 (2) , 97-99
The skinny on metabolic syndrome in adolescents
The skinny on metabolic syndrome in adolescents
- 1 April 2016
- Published by AME Publishing Company in Translational Pediatrics
- Vol. 5 (2) , 97-99
The skinny on metabolic syndrome in adolescents
The skinny on metabolic syndrome in adolescents
- 1 April 2016
- Published by Elsevier in Clinical Biochemistry
- Vol. 49 (6) , 505-507
Monocyte cell adhesion molecule receptors in nascent metabolic syndrome
- 1 April 2016
- Published by Elsevier in Clinical Biochemistry
- Vol. 49 (6) , 505-507
Monocyte cell adhesion molecule receptors in nascent metabolic syndrome
- 11 March 2016
- Published by Elsevier in Journal of Diabetes and its Complications
- Vol. 30 (6) , 1186-1191
The role of the high-mobility group box1 protein–Toll like receptor pathway in diabetic vascular disease
- 11 March 2016
- Published by Elsevier in Journal of Diabetes and its Complications
- Vol. 30 (6) , 1186-1191
The role of the high-mobility group box1 protein–Toll like receptor pathway in diabetic vascular disease
- 1 March 2016
- Published by Georg Thieme Verlag KG in Experimental and Clinical Endocrinology & Diabetes Reports
- Vol. 3 (01) , e8-e10
Statin Intolerance in a Patient with Gilberts Syndrome and Hypercholesterolemia
Background: Statin intolerance especially myalgias can be a serious problem. Whilst it is well know that drugs that compete for Cytochrome 450 system can result in myalgias there is sparse data on the role of glucuronidation of statins contributing to statin intolerance We report on a 60 year old male with Hypercholesterolemia (HC) who was referred for management of his HC since he had statin intolerance manifesting as myalgias and was shown to have Gilbert’s Syndrome. Case Report: Investigation of this patient revealed he had Familial Combined Hyperlipidemia with a LDL-cholesterol of 189 mg/dl. He was also diagnosed with Gilbert’s Syndrome since he had elevated unconjugated bilirubin with no evidence of liver disease or hemolysis. The combination of Niacin, Cholestyramine and ezetimibe resulted in a successful decrease in his LDL-cholesterol to 114 mg/dl. Discussion: We believe that his Gilberts Syndrome resulted in an impairment in glucuronidation of statin drugs resulting in an increase in free drug levels and myalgias. We caution that clinicians should consider this possibility when confronted with a patient with both isolated elevations of unconjugated bilirubin and increase LDL-cholesterol levels before commencing statin therapy.
- 1 March 2016
- Published by Georg Thieme Verlag KG in Experimental and Clinical Endocrinology & Diabetes Reports
- Vol. 3 (01) , e8-e10
Statin Intolerance in a Patient with Gilberts Syndrome and Hypercholesterolemia
Background: Statin intolerance especially myalgias can be a serious problem. Whilst it is well know that drugs that compete for Cytochrome 450 system can result in myalgias there is sparse data on the role of glucuronidation of statins contributing to statin intolerance We report on a 60 year old male with Hypercholesterolemia (HC) who was referred for management of his HC since he had statin intolerance manifesting as myalgias and was shown to have Gilbert’s Syndrome. Case Report: Investigation of this patient revealed he had Familial Combined Hyperlipidemia with a LDL-cholesterol of 189 mg/dl. He was also diagnosed with Gilbert’s Syndrome since he had elevated unconjugated bilirubin with no evidence of liver disease or hemolysis. The combination of Niacin, Cholestyramine and ezetimibe resulted in a successful decrease in his LDL-cholesterol to 114 mg/dl. Discussion: We believe that his Gilberts Syndrome resulted in an impairment in glucuronidation of statin drugs resulting in an increase in free drug levels and myalgias. We caution that clinicians should consider this possibility when confronted with a patient with both isolated elevations of unconjugated bilirubin and increase LDL-cholesterol levels before commencing statin therapy.